Pancreatic Cancer Research

ResearcherShandong UniversityActive in the last 2 years

Hanxiang Zhan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5489-1142; OpenAlex author ID A5102797012. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 4 papers · 2025: 3 papers

Papers 15

  1. Mitochondria-centric lipid metabolism and inter-organelle crosstalk in pancreatic Cancer: Unveiling novel therapies. Last author DOI 10.1016/j.canlet.2025.217965↗
  2. Genetic association of lipid-lowering drug target genes with pancreatic cancer: a Mendelian randomization study. Last author DOI 10.1038/s41598-025-87490-x↗
  3. [Clinicopathologic features and lipid profile characteristics of early-onset pancreatic cancer]. Last author DOI 10.3760/cma.j.cn112139-20240826-00397↗
  4. Crosstalk between pancreatic cancer and adipose tissue: Molecular mechanisms and therapeutic implications. Last author DOI 10.1016/j.bbrc.2024.151012↗
  5. Corrigendum to "LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway" [Cancer Lett.374 (2016) 261-27… Co-author DOI 10.1016/j.canlet.2024.217239↗
  6. Comment on "Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection". Last author DOI 10.1097/as9.0000000000000376↗
  7. [Research status of the tumor stroma ratio in prognosis and treatment of pancreatic cancer]. Last author DOI 10.3760/cma.j.cn112139-20240414-00183↗
  8. [Changes of serum lipid profiles and the correlation analysis in clinic-pathological features of pancreatic cancer patients]. Last author DOI 10.3760/cma.j.cn112139-20220209-00054↗
  9. Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms. Last author DOI 10.1016/j.pan.2019.08.008↗
  10. Immunotherapy for pancreatic cancer: A long and hopeful journey. Last author DOI 10.1016/j.canlet.2018.03.040↗
  11. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Co-author DOI 10.1002/cam4.1071↗
  12. Early detection of pancreatic cancer: Where are we now and where are we going? Last author DOI 10.1002/ijc.30670↗
  13. LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. Co-author DOI 10.1016/j.canlet.2016.02.018↗
  14. Pancreatic cancer stem cells: new insight into a stubborn disease. Co-author DOI 10.1016/j.canlet.2014.12.004↗
  15. Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer. Co-author DOI 10.1186/s12957-015-0510-0↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiyao Fan · 7 shared papers, 2022–2025 · strength 2.20
  2. Jianwei Xu · 8 shared papers, 2015–2024 · strength 0.74
  3. Xin Gao · 2 shared papers, 2024–2025 · strength 0.66
  4. Sanyuan Hu · 7 shared papers, 2015–2019 · strength 0.53
  5. Bin Zhou · 2 shared papers, 2019–2024 · strength 0.41
  6. Bohan Su · 1 shared paper, 2025 · strength 0.37
  7. Runxian Wang · 1 shared paper, 2025 · strength 0.33
  8. Boyu Diao · 1 shared paper, 2024 · strength 0.31
  9. Chaoyu Pang · 1 shared paper, 2025 · strength 0.30
  10. Ce Li · 2 shared papers, 2016–2024 · strength 0.27
  11. Lei Wang · 3 shared papers, 2017–2018 · strength 0.25
  12. Guangyong Zhang · 3 shared papers, 2015–2018 · strength 0.23
  13. Bin Zhou · 3 shared papers, 2016–2018 · strength 0.22
  14. San-yuan Hu · 1 shared paper, 2024 · strength 0.21
  15. Jianmin Yang · 1 shared paper, 2022 · strength 0.16
  16. Lei Wang · 2 shared papers, 2015–2016 · strength 0.12
  17. Han Liu · 1 shared paper, 2019 · strength 0.10
  18. Yunshan Wang · 1 shared paper, 2019 · strength 0.10
  19. Taiping Zhang · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.